Publicacions en col·laboració amb investigadors/es de Instituto de Investigación Sanitaria del Principado de Asturias (21)

2024

  1. Differences in the clinical and hormonal presentation of patients with familial and sporadic primary aldosteronism

    Frontiers in Endocrinology, Vol. 15

  2. Impact of Applying the Global Lung Initiative Criteria for Airway Obstruction in GOLD Defined COPD Cohorts: The BODE and CHAIN Experience

    Archivos de Bronconeumologia, Vol. 60, Núm. 1, pp. 10-15

  3. Impact of primary aldosteronism on kidney function: Results from the SPAIN-ALDO registry

    Journal of Hypertension, Vol. 42, Núm. 10, pp. 1805-1812

  4. Is adrenal venous sampling always necessary to differentiate between unilateral and bilateral primary aldosteronism? Lesson from the SPAIN-ALDO register

    Endocrine, Vol. 84, Núm. 2, pp. 683-693

  5. Renin as a Biomarker to Guide Medical Treatment in Primary Aldosteronism Patients. Findings from the SPAIN-ALDO Registry

    High Blood Pressure and Cardiovascular Prevention, Vol. 31, Núm. 1, pp. 43-53

2023

  1. Autonomous cortisol secretion in patients with primary aldosteronism: prevalence and implications on cardiometabolic profile and on surgical outcomes

    Endocrine Connections, Vol. 12, Núm. 9

  2. Corrigendum to “Differences between childhood- and adulthood-onset eosinophilic esophagitis: An analysis from the EoE connect registry” [Digestive and Liver Disease Volume 55, Issue 3, March 2023, Pages 350–359] (Digestive and Liver Disease (2023) 55(3) (350–359), (S1590865822007289), (10.1016/j.dld.2022.09.020))

    Digestive and Liver Disease

  3. Differences between childhood- and adulthood-onset eosinophilic esophagitis: An analysis from the EoE connect registry

    Digestive and Liver Disease, Vol. 55, Núm. 3, pp. 350-359

  4. Prevalence, risk factors and evolution of diabetes mellitus after treatment in primary aldosteronism. Results from the SPAIN-ALDO registry

    Journal of Endocrinological Investigation, Vol. 46, Núm. 11, pp. 2343-2352

  5. The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

    Hepatology (Baltimore, Md.), Vol. 78, Núm. 3, pp. 878-895

2022

  1. Accurate and timely diagnosis of Eosinophilic Esophagitis improves over time in Europe. An analysis of the EoE CONNECT Registry

    United European Gastroenterology Journal, Vol. 10, Núm. 5, pp. 507-517

  2. Adrenal venous sampling in primary aldosteronism: Experience of a Spanish multicentric study (Results from the SPAIN-ALDO Register)

    Endocrine, Vol. 78, Núm. 2, pp. 363-372

  3. Differences in the presentation and evolution of primary aldosteronism in elderly (≥65 years) and young patients (<65 years)

    Endocrine Connections, Vol. 11, Núm. 6

  4. RICORS2040: The need for collaborative research in chronic kidney disease

    Clinical Kidney Journal, Vol. 15, Núm. 3, pp. 372-387

  5. YES1 Is a Druggable Oncogenic Target in SCLC

    Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1387-1403

2021

  1. SLITRK2, an X-linked modifier of the age at onset in C9orf72 frontotemporal lobar degeneration

    Brain, Vol. 144, Núm. 9, pp. 2798-2811

2020

  1. Expression of GPR55 and either cannabinoid CB1 or CB2 heteroreceptor complexes in the caudate, putamen, and accumbens nuclei of control, parkinsonian, and dyskinetic non-human primates

    Brain Structure and Function, Vol. 225, Núm. 7, pp. 2153-2164

  2. Phage therapy: Unexpected drawbacks to reach hospitals

    Future Virology, Vol. 14, Núm. 12, pp. 779-782

  3. Sarcoma treatment in the era of molecular medicine

    EMBO Molecular Medicine, Vol. 12, Núm. 11

2019

  1. Targeting CB1 and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson’s Disease

    Molecular Neurobiology, Vol. 56, Núm. 8, pp. 5900-5910